188
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia

, , , , , , , , & show all
Pages 2439-2447 | Received 25 Aug 2014, Accepted 01 Dec 2014, Published online: 21 Jan 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yangyang Xu, Xiangxiang Zhou, Ying Li, Ya Zhang & Xin Wang. (2019) Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine. Leukemia & Lymphoma 60:5, pages 1266-1274.
Read now

Articles from other publishers (3)

Huiyu Yang, Jie Wang, Suliman Khan, Yuanying Zhang, Kuicheng Zhu, Enhui Zhou, Meiyuan Gong, Bingrong Liu, Quancheng Kan & Qi Zhang. (2021) Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells. Anti-Cancer Drugs 33:1, pages e444-e452.
Crossref
Marinela Bostan, Gabriela Ion, Mirela Mihaila, Viviana Roman, Carolina Constantin & Monica Teodora Neagu. 2022.
M van Gelder, M H van Oers, W G Alemayehu, M C J Abrahamse-Testroote, J J Cornelissen, M E Chamuleau, P Zachée, M Hoogendoorn, M Nijland, E J Petersen, A Beeker, G-J Timmers, L Verdonck, M Westerman, O de Weerdt & A P Kater. (2016) Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. Bone Marrow Transplantation 51:6, pages 799-806.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.